Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:UBX

UNITY Biotechnology (UBX) Stock Price, News & Analysis

UNITY Biotechnology logo

About UNITY Biotechnology Stock (NASDAQ:UBX)

Key Stats

Today's Range
$0.20
$0.20
50-Day Range
$0.18
$0.88
52-Week Range
$0.20
$1.23
Volume
N/A
Average Volume
808,608 shs
Market Capitalization
$3.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50
Consensus Rating
Hold

Company Overview

UNITY Biotechnology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
30th Percentile Overall Score

UBX MarketRank™: 

UNITY Biotechnology scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    UNITY Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    UNITY Biotechnology has a consensus price target of $1.50, representing about 649.6% upside from its current price of $0.20.

  • Amount of Analyst Coverage

    UNITY Biotechnology has received no research coverage in the past 90 days.

  • Read more about UNITY Biotechnology's stock forecast and price target.
  • Earnings Growth

    Earnings for UNITY Biotechnology are expected to grow in the coming year, from ($1.45) to ($1.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of UNITY Biotechnology is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of UNITY Biotechnology is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    UNITY Biotechnology has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for UBX.
  • Dividend Yield

    UNITY Biotechnology does not currently pay a dividend.

  • Dividend Growth

    UNITY Biotechnology does not have a long track record of dividend growth.

  • Search Interest

    1 people have searched for UBX on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, UNITY Biotechnology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.80% of the stock of UNITY Biotechnology is held by insiders.

  • Percentage Held by Institutions

    29.49% of the stock of UNITY Biotechnology is held by institutions.

  • Read more about UNITY Biotechnology's insider trading history.
Receive UBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UNITY Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

UBX Stock News Headlines

$30 stock to buy before Starlink goes public (WATCH NOW!)
A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.tc pixel
UBX Unity Biotechnology, Inc. - Seeking Alpha
See More Headlines

UBX Stock Analysis - Frequently Asked Questions

UNITY Biotechnology, Inc. (NASDAQ:UBX) announced its earnings results on Tuesday, April, 22nd. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.43).

UNITY Biotechnology's stock reverse split on the morning of Thursday, October 20th 2022.The 1-10 reverse split was announced on Thursday, October 20th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 20th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

UNITY Biotechnology (UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that UNITY Biotechnology investors own include Plug Power (PLUG), NVIDIA (NVDA), NIO (NIO), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Enovix (ENVX) and Nokia (NOK).

Company Calendar

Last Earnings
4/22/2025
Today
5/07/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UBX
CIK
1463361
Fax
N/A
Employees
60
Year Founded
2009

Price Target and Rating

High Price Target
$2.00
Low Price Target
$1.00
Potential Upside/Downside
+649.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.62)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$25.99 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-246.82%
Return on Assets
-58.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.95
Quick Ratio
1.95

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
0.51

Miscellaneous

Outstanding Shares
17,212,000
Free Float
16,214,000
Market Cap
$3.44 million
Optionable
Optionable
Beta
0.92

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:UBX) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners